As the $1 trln drugmaker’s smash-hit obesity treatments shrink waistlines, its cashflow and valuation are swelling. Gilead, Moderna and Pfizer show how hard it is to put such a windfall to good use. Deals may just destroy value. Buying back wildly expensive stock definitely will.
